A Study of Single-Dose Gabapentin in Subjects With Transient Insomnia Induced by a Sleep Phase Advance
Public ClinicalTrials.gov record NCT00666939. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter Study Of Gabapentin 100 mg and 250 mg in Transient Insomnia Induced By A Sleep Phase Advance
Study identification
- NCT ID
- NCT00666939
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Enrollment
- 773 participants
Conditions and interventions
Conditions
Interventions
- Gabapentin Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2004
- Primary completion
- Not listed
- Completion
- Dec 31, 2004
- Last update posted
- Feb 1, 2021
2004 – 2005
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | San Diego | California | 92108 | — |
| Pfizer Investigational Site | Ocala | Florida | 34471 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30328 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30342 | — |
| Pfizer Investigational Site | Metairie | Louisiana | 70001 | — |
| Pfizer Investigational Site | New York | New York | 10025 | — |
| Pfizer Investigational Site | Thornwood | New York | 10594 | — |
| Pfizer Investigational Site | Raleigh | North Carolina | 27612 | — |
| Pfizer Investigational Site | Duncansville | Pennsylvania | 16635 | — |
| Pfizer Investigational Site | Johnstown | Pennsylvania | 15904 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00666939, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 1, 2021 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00666939 live on ClinicalTrials.gov.